

Modeling and Simulation of Molecular Mechanism of Action of Dietary Polyphenols on the Inhibition of Anti-Apoptotic PI3K/AKT Pathway

Pedro Pablo González-Pérez¹, Maura Cárdenas-García²

¹Departamento de Matemáticas Aplicadas y Sistemas, Universidad Autónoma Metropolitana, México, D.F., México ²Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, México Email: pgonzalez@correo.cua.uam.mx, maura.cardenas@correo.buap.mx

Received May 9, 2013; revised June 9, 2013; accepted June 17, 2013

Copyright © 2013 Pedro Pablo González-Pérez, Maura Cárdenas-García. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

In recent years, the role of dietary phenolic compounds in the regulation of cellular metabolism in normal and pathological conditions has become increasingly important in cancer research. In most cases, the molecular mechanism of action related to the anticarcinogenic effect of phenolic compounds has been studied *in vitro* and in animal models, but these studies are still not complete. It is precisely here where in silico approaches can be an invaluable tool for complementing *in vitro* and *in vivo* research. In this paper, we adopt a tuple space-based modeling and simulation approach, and show how it can be applied to the simulation of complex interaction patterns of intracellular signaling pathways. Specifically, we are working to explore and to understand the molecular mechanism of action of dietary phenolic compounds on the inhibition of the PI3K/AKT anti-apoptotic pathway. As a first approximation, using the tuple spacesbased in silico approach, we model and simulate the anti-apoptotic PI3K/AKT pathway in the absence and presence of phenolic compounds, in order to determine the effectiveness of our platform, to employ it in future prediction of experimentally non visualized interactions between the pathway components and phenolic compounds.

Keywords: Anti-Apoptotic Intracellular Signaling Pathway; Computer Simulation; Self-Organizing Coordination; Tuple-Based Model

1. Introduction

The phenolic compounds present in plants have attracted much attention. In general, the main action of these compounds is the chemical relationships of plants with their environment. They are found in virtually all plants and therefore are integrated in the human diet; the role of phenolic compounds in the regulation of cellular metabolism in normal and pathological conditions has become increasingly important interest area [1]. Once incorporated into the human diet, phenolic compounds may have varied effects. As antioxidants, they have many benefits for health, can protect cell structures from attack by reactive oxygen species and thus limit the risk of diseases associated with oxidative stress. Numerous studies have attributed to the dietary phenolic compounds an important role in preventing cardiovascular diseases, cancer, osteoporosis, diabetes mellitus and neurodegenerative diseases [2].

During recent years, various papers have been published that suggest a variety of other mechanisms, through which polyphenols could exert part of their beneficial actions on biological systems. They include polyphenols ability to modulate the activity of enzymes such as telomerase [3], cyclooxygenase [4,5] and lipoxygenase [6,7], or their ability to interact with signal transduction and cellular receptors [8-10]. The effects in the treatment of HIV infection were described [11], as well as their anti-inflammatory [12,13], anti atherogenic, anti-diabetic [14], and anti-obesity [15] properties.

The cell has a self-destruction system that starts and operates in a regulated manner. It is called apoptosis and includes the decision to start self-destruction as well as the proper execution of the apoptotic program. As such it requires the coordinated activation and execution of multiple subprograms. On the other hand, cancer cells initiate anti-apoptotic programs since their goal is to survive. Tumorigenesis and tumour progression are the result of imbalance among cell proliferation, differentiation and apoptosis. Thus, in tumour cells, activation of the antiapoptotic signaling pathway associated with phosphatidyl inositol-3-kinase (PI3K), mitogen-activated protein kinases (MAPKs) and protein kinase C (PKC) occurs. The tumour cells survive after exposure to stress and these proteins are only expressed at high levels in transformed cells [16]. Dietary polyphenols may interfere at different developmental stages of carcinogenesis through several mechanisms, and its effects will depend on the tissue or cell type, as well as on the dose and duration of treatment.

In most cases, the molecular mechanism of action related to the anticarcinogenic effect of polyphenols has been studied *in vitro* and in animal models, but these studies are still not complete. It is precisely here that in silico approaches can be an invaluable tool for complementing *in vitro* and *in vivo* research.

In this paper, we propose an in silico approach based on biochemical tuple spaces [17], and show how it can be applied to the simulation of complex interaction patterns of intracellular signaling pathways, particularly in the simulation of molecular mechanism of action of dietary polyphenols on the inhibition of anti-apoptotic intracellular pathways.

2. BTSSOC-Based in Silico Approach

The simulation approach presented here is based on the notion of Biochemical Tuple Space for Self-Organizing Coordination (BTSSOC), as introduced in [17] for pervasive services ecosystems. In BTSSOC each tuple space works as a compartment where biochemical reactions take place, chemical reactants are represented as tuples, and biochemical laws are represented as coordination laws by the coordination abstraction. Technically, biochemical tuple spaces are built as ReSpecT tuple centres [18], running upon a TuCSoN coordination infrastructure [19]. Tuples are logic-based tuples, while biochemical laws are implemented as ReSpecT specification tuples—so they can be inserted, modified and removed from the compartment (the type centre) via simple Linda-based coordination primitives [20].

As can be seen from the **Figure 1**, the high level architecture of the BTSSOC-based in silico approach is defined in terms of the following two main modules:

- BTSSOC-based model.
- GUI application.

2.1. The BTSSOC-Based Model

This module represents our general model for intracellular signaling pathways based on the notion of Biochemical Tuple Spaces for Self-Organizing Coordination (BT-SSOC). A detailed explanation of this model can be

- Tuple centres.
- Chemical reaction sets.
- Reactants (R).
- Coordination laws.

The cellular compartments involved in signaling pathways are represented as biochemical tuple spaces—that is, tuple centres suitably programmed with the ReSpecT logic language [18]. In particular, each biochemical tuple space is built around a ReSpecT chemical engine, whose core is an action selection mechanism based on Gillespie algorithm [22]—an algorithm typically used to simulate systems of chemical/biochemical reactions efficiently and accurately—to execute chemical reactions with the proper rate.

The components representing intracellular signaling elements must focus only on the transformation of input signals into output signals, according to the behavior of the corresponding signaling element. So, if the main task of the signaling components (*i.e.*, those modeling membrane receptors, proteins, enzymes and genes) is to perform chemical reactions for signal transduction, the most appropriate solution in the BTSSOC-based approach is to model each signaling component as the set of the chemical reactions that defines its behavior.

The elements recorded as tuples in a tuple centre (*i.e.*, reactants and concentration) represent the information about the two main sorts of intracellular signal in the model: signaling molecules and activation/deactivation signals. Such elements are the inputs and outputs for the chemical reactions that belong to each tuple centre, and set their activation, duration, or deactivation either directly or indirectly. As a result, in the same way as in



Figure 1. A high-level architecture for the BTSSOC-based bioinformatics platform.

biological systems, evolution depends on the concentration and state of the reactants.

Biochemical laws are represented as coordination laws by the coordination abstraction, in the model the tuple concentration evolves over time according to a rate in the same way as chemical substances in a solution. Also, BTSSOC laws allow for tuple diffusion, making it possible for products to cross compartment boundaries as a result of biochemical reactions.

2.2. The GUI Application

The module GUI application provides the tools for users so that they can perform the following activities:

- Creation, modification and visualization of the simulation components—e.g., cellular compartments, signaling components, signaling molecules and cellular processes—either during the implementation of the simulation or during the execution of it.
- Feedback on the results provided by the simulation run—e.g., 1) the behavior of the simulated system over time, as a result of the interactions that take place between its components, and 2) the current state of each component (*i.e.*, signaling elements) of the simulation.

As shown in **Figure 1**, the module GUI application is composed by three main types of components:

- User agent.
- Monitor agents.

Intracellular Simulation - RasMAPKSimulation30012012D.bts

• View.

Here we refer only to the component View, which corresponds to the graphical user interface of BTS-SOCbased in silico approach (BTS-SOC GUI). This component contains four major elements: 1) a main menu, 2) a drawing canvas, 3) the buttons to start and stop the simulation, and 4) the Tucson command line. The functionality distributed among these elements is precisely what allows BTSSOC infrastructure appearing to the users as a true virtual laboratory, where the experiments can be initiated, developed, stored, recovered, modified, visualized, restarted, and stopped. **Figures 2** and **3** show two BTSSOC GUI snapshots.

3. The Inhibition of Anti-Apoptotic PI3K/AKT Pathway

In this paper we simulate the potential role of polyphenols induced apoptosis in human cells of breast cancer [23-27]. According to reports in the literature, polyphenols inhibit the proliferation of MCF-7 cells in a concentration and time dependent manner [23,24].

As mentioned, activation of anti-apoptotic PI3K pathway is frequently observed in many human cancer cells [28]. Survivin, a member of the family of inhibitors of apoptosis, is expressed in most human cancers but is undetectable in normal differentiated tissues. Survivin is elevated in cancer cells and it is induced by some growth factors through the activation of PI3K. Forced expression

 Project Add_ Modify_Remove_Stow_Charts Events Log

 nucleus_cytosol_juxtamembrane

 mucleus_cytosol_juxtamembrane

 Start Simulation

 Story Simulation

 Story Simulation

 Tocon commands Insert any turson command here

 Einure 2. The main CILL of PETSSOC-based commuter simulation showing its faur main commonants: 1) the main manu loc

Figure 2. The main GUI of BTSSOC-based computer simulation showing its four main components: 1) the main menu, located on the bottom of the screen, 2) the drawing canvas, represented by the large central area of the screen, 3) the buttons to start and stop the simulation, placed on the far right of the screen, and 4) the Tucson command line, located on the bottom of the screen.





Figure 3. The drawing canvas of the BTSSOC GUI. Different charts showing the state of the simulation components and its interactions can be supported by the drawing canvas.

of PTEN leads to decreased levels of survivin mRNA. PI3K regulates the expression of survivin through the activation of Akt. P70S6K1 over expression alone is sufficient to induce survivin expression. PI3K/Akt/p70S6K1 pathway is essential for the regulation of mRNA expression of survivin.

4. The Incremental Modeling and Simulation Methodology

As can be seen in **Figure 4**, modeling an intracellular signaling network with the BTSSOC-based approach can be handled as an incremental process of definition and refinement of the signaling pathways and components



Figure 4. Incremental modeling process of anti-apoptotic signaling pathway PI3K/AKT, the cube represents the characteristics of our current work and moves it according to our needs.

in the network.

The modeling process begins by considering a single signaling pathway from the complex network of the antiapoptotic signaling pathways. The PI3K/AKT pathway has been selected for this purpose. At the beginning of the modeling process it is appropriate to consider only the main features of the components involved in the antiapoptotic signal transduction, *i.e.* those needed for achieving a comprehensible and functional simulation. The incremental development of the modeling process proceeds by incorporating other signaling components, defining the interactions among them (set of chemical reactions), and including other features of the biochemical elements that are required for the accurate modeling of the signaling system. Clearly, the more the modeling process preserves the essential features of signal transduction, the more the intracellular signaling model becomes significant.

5. Results and Discussion

As can be seen in **Figure 5**, the simulation presented here represents the PI3K/AKT signaling pathway in the presence of phenolic compounds in a breast cancer cell. The pathway begins with the growth or survival signals, these signals can lead to disruption of apoptosis, but in the presence of phenolic compounds apoptosis may continue.

5.1. Modeling PI3K/AKT Anti-Apoptotic Signaling Pathway

The PI3K/AKT pathways influence either directly or indirectly whether a cell will undergo apoptosis. These events are probably essential for the survival of both cancer and normal cell. In this paper, we start with a minimalist model (see **Figure 4**) where each signaling component belonging to PI3K/AKT pathway is described by the following attributes:

- Identity.
- Concentration in each cellular compartment.
- Free concentration.
- Bound concentration.
- Cellular compartment to which it belongs.
- Chemical reactions involving the component and the order in which they occur according to the affinity of the components.
- Reaction temporality situation.

Such a coarse-grained modeling strategy leads to an initial BTSSOC-based model of the PI3K/AKT signaling pathways, whose main features are summarized in **Tables 1** and **2**.

As far as this initial PI3K/AKT anti-apoptotic intracellular signaling model is concerned, only two further remarks are required here. For each chemical reaction, 1) the interaction between reactants is set to 1:1 in terms of

Cellular compartment	Reactions					
Extracellular space and membrane	$RTK + SF \rightarrow RTK^*@cytosol$					
	$\mathrm{RTK}^* + \mathrm{PI3K} \longrightarrow \mathrm{PI3K}^* + \mathrm{RTK}^*$					
	$RTK^* + Ras \rightarrow Ras^* + RTK^*$					
	$\mathrm{PI3K}^* + \mathrm{PIP3} \longrightarrow \mathrm{PIP3}^* + \mathrm{PI3K}^*$					
	$PI3K^* + AKT \rightarrow AKT^* + PI3K^*$					
	$PIP3^* + AKT \rightarrow AKT^*$					
	$PIP3^* + PDK1 \rightarrow PDK1^*$					
	$PIP3^* + PDK2 \rightarrow PDK2^*$					
	$PDK1^* + AKT \rightarrow AKT^* + PDK1$					
	$PDK2^* + AKT \rightarrow AKT^* + PDK2$					
	$AKT^* + AKT \rightarrow 2AKT^*$					
	$AKT^* + IKK \rightarrow IKK^* + AKT$					
	$AKT^* + XIAP \rightarrow XIAP^*$ @nucleus + AKT^*					
Cytosol	$AKT^* + Raf \rightarrow Raf1^*@nucleus + AKT^*$					
	$AKT^* + GSK3^* \rightarrow GSK3 + AKT$					
	$AKT^* + Mdm2 \rightarrow Mdm2^* + AKT$					
	$\text{PTEN}^* + \text{PIP3}^* \rightarrow \text{PIP3} + \text{PTEN}$					
	$SHIP2^* + PI3K^* \rightarrow PI3K + SHIP2$					
	$\rm IKK^* + \rm IkB/\rm NFkB \rightarrow \rm IkB/\rm NFkB^* + \rm IKK$					
	$Ras^* + PI3K \rightarrow PI3K^* + Ras$					
	$AKT^* \rightarrow AKT^*$ @nucleus					
	$Mdm2 + p53^* \rightarrow Mdm2 + p53$					
	$4p53^* \rightarrow 2p53^*$ @nucleus					
	$\text{GSK3}^* + \text{BAD}/1433^* \rightarrow \text{BAD}/1433 + \text{GSK3}$					
	$BAD/1433^* + BclXL^* \rightarrow BclXL@nucleus + BAD1433^*$					
	$BAD/1433^* + Bcl2^* \rightarrow Bcl2@nucleus + BAD1433^*$					
NC: 1 11	$4\text{GSK3}^* \rightarrow 2\text{GSK3}^*$ @cytosol + 2GSK3^* @nucleus					
Mitochondria	$4BclXL^* \rightarrow 2BclXL^*@cytosol + 2BclXL^*$					
	$AKT^* + TSC1 \rightarrow TSC1^* + AKT$					
	$AKT^* + TSC2 \rightarrow TSC2^* + AKT$					
	$AKT^* + AKT \rightarrow 2AKT^*$					
	$\text{TSC1/TSC2}^* + \text{mTOR}^* \rightarrow \text{mTOR} + \text{TSC1/TSC2}$					
Nucleus	$Raf1^* + p70S6K \rightarrow p70S6K^* + Raf1$					
	$GSK3^* + p21Cip1^* \rightarrow p21Cip1 + GSK3$					
	$GSK3^* + cyclinD1^* \rightarrow cyclinD1 + GSK3$					
	$mTOR^* + p70S6K \rightarrow p70S6K^* + mTOR$					

Table 1. Modeling the signal components belonging to antiapoptotic signaling pathway. The symbol @ on the right side of an equation indicates the cellular compartment in which the resultant reactant must be registered.

Table	2.	Initial	concentr	ations	of	the	reactants	belonging	to
anti-a	poj	ptotic I	PI3K/AK	Γ signa	alir	ng pa	athway.		

Component	Identity	Concentration
SF	Survival factor	0.1 nM [29]
RTK	Receptor tyrosine kinase	0.25 µM [29]
PI3K	Phosphatidylinositide 3-kinases	0.1 µM [30]
Ras	Small GTPase	18.9 µM [31]
Ras	Small GTPase	18.9 µM [31]
SHIP2	Phosphatase that regulates the PI3K/AKT pathway	0.1 µM [31]
PTEN (SHIP1)	Phosphatase that regulates the PI3K/AKT pathway	0.27 µM [31]
Raf	Serine/threonine-protein kinase	0.07 µM [31]
PDK1	3-phosphoinositide dependent protein kinase-1	1.0 µM [32]
PDK2	Pyruvate dehydrogenase	1.0 µM [32]
PIP3	Phosphatidylinositol (3,4,5)-triphosphate	7.0 µM [32]
SF	Survival factor	0.1 nM [29]
IKK	IkappaB kinase	0.1 µM [32]
AKT	(PKB) Serine/Threonine specific protein kinase	0.2 µM [33,35]
XIAP	X-linked inhibitor of apoptosis protein	0.1 µM [34]
P70S6K	Serine/threonine kinase	0.17 µM [35]
mTOR	Serine/threonine kinase	0.6 µM [31,35]
TSC1	Tumor suppressor 1	1.0 µM [36]
TSC2	Tumor suppressor 2	0.1 µM [36]
GSK3	Serine/threonine kinase	0.1 µM [37]
Mdm2	Negative regulator of the p53 tumor suppressor	0.1 µM [38]
p53	Tumor suppressor	0.1 µM [23]
Cyclin D1	G1/S specific cyclin	0.1 µM [39]
p21	Cyclin-dependent kinase inhibitor 1	0.1 µM [40]
Bcl2	Regulator protein	0.1 µM [41]
1433	Regulator protein	0.1 µM [32]
Bad	Bcl-2 associated death promoter	0.1 µM [40]
BclXL	Transmembrane molecule	0.1 µM [24]
PhC	Phenolic Compound	34 µM [27]

number of units—that is, 1 unit of the reactant A is required for 1 unit of the reactant B; 2) the initial rate is set to a very small value (*i.e.*, rate = 0.001), allowing the Gillespie algorithm to show the evolution of chemical



Figure 5. The anti-apoptotic PI3K/AKT pathway.

reactions in a straightforward way.

5.2. Setting the BTSSOC-Based Simulation Framework

A tuple centre (BTS) is required for each cellular compartment involved in the signaling pathway to be simulated. In our study, the anti-apoptotic PI3K/AKT signaling pathway begins in the extracellular space, continues in the membrane, it goes through the cytosol, some signaling components in and out of the mitochondria, finally ending in the nucleus. In our first simulation the ex- tracellular space and membrane are represented in a sin- gle compartment. Therefore, four tuple centres (mem- brane, cytosol, mitochondria and nucleus) are required to model four intracellular compartments—see **Figure 6**.

Next step is aimed at making every BTS to know its neighbors—*i.e.*, the cellular compartments that follow it in the signaling pathway.

Our minimal case scenario is about a downstream signaling pathway: therefore, every BTS has only one neighbor here, whereas the infrastructure supports modeling multiple neighbors. Once every BTS knows its own neighbor, reactions producing reactants meant to cross the compartment boundaries can be published in the BTS, and made available in the linked compartment.

In order to set up the simulation system, reactants should be introduced in the BTS. First of all, each reactant belongs to a specific cellular compartment—so, it has to be put in the appropriate BTS. Initially, only the pre-existing reactants—*i.e.*, those reactants already in the compartments before the signaling pathway is activated—have to be put in the BTS.

As an example, we consider a reaction belonging to the cytosol BTS, and described in Equation (2). Among the reactants, only PI3K is initially present in cytosol BTS, while RTK^{*} is the product of another reaction— Equation (1)—in the membrane BTS, and needs not to be in the compartment at the beginning of the simulation.

In order to place a reactant "A" in a BTS, a tuple of the kind reactant (A, concentration) has to be published in the corresponding tuple centre—there, concentration is an integer number that represents the amount of that element in the cellular compartment expressed in terms of the number of units of such a reactant.

S Intracellular Simulation - PI3KAKT-Polyphenols-20121219-05.bts	tim latteresters for the safety improved ballet a	
Project Add Modify Remove Show Charts Events Log		
nucleus mitochondria cytosol membrane		
	Bata	7
Ldw AKT* + Mdm2 > Mdm2* + AKT	0.0010	
	0.0010	-
	0.0010	-
AKT + YIAD > YIAD = 0 purchase + AKT*	0.0010	-
AKT* + Raft -> Raft* @ nucleus + AKT*	0.0010	-
$Mdm^2 + n52^* \rightarrow Mdm^2 + n53$	0.0010	-
AKT* + COK2* -> COK2 + AKT	0.0010	-
4n52* -> 2n52* @ nucleus	0.0010	-
4955 - 2955 @ nucleus CSK3* + B4D1//33* -> B4D1//33 + CSK3	0.0010	
BAD1433* + BdXI * -> BdXI @ nucleus + BAD1433*	0.0010	
AKT* -> AKT* @ nucleus	0.01	
PI3K* + PIP3 -> PIP3* + PI3K*	0.0010	
PI3K* + AKT -> AKT* + PI3K*	0.0010	
	0.0010	-
PIP3* + PDK1 -> PDK1*	0.0010	
PIP3* + PDK2 -> PDK2*	0.0010	Ctart Cimulation
PDK1* + AKT -> AKT* + PDK1	01	Start Simulation
PDK2* + AKT -> AKT* + PDK2	01	Stop Simulation
PTEN* + PIP3* -> PIP3 + PTEN	0.0010	
SHIP2* + PI3K* -> PI3K + SHIP2	0.0010	
Ras* + PI3K -> PI3K* + Ras	0.0010	
RTK* + PI3K -> PI3K* + RTK*	0.0010	
BAD1433* + Bcl2* -> Bcl2 @ nucleus + BAD1433*	0.0010	
IKK* + IkBNFkB -> IkBNFkB* + IKK	0.0010	
PhC + PI3K* -> PI3K	0.0010	
PhC + AKT* -> AKT	0.0010	
		-
		╝
Tucson commands Insert any tucson command here		Execute
	🖇 Add Law	
	Law: RTK* +Ras -> Ras* + RTK*	
	Rate: 0.001	

Figure 6. Publication and inspection of chemical reactions in the cytosol BTS.

Ok

The last step in setting up the simulation is the introduction of the reactions modeling the behavior of signaling pathway. As for the reactants, it is necessary before proceeding to clearly allocate the whole set of reactions in the different compartments, in order to publish them in the proper BTS. As can be seen from **Figure 6**, the BTS-SOC GUI allows the user to publish the chemical reactions in "everyday language", using the notation commonly employed when writing these equations. In our model, based on the Gillespie algorithm, every chemical reaction has a rate that expresses (along with the concentration of the input elements) the probability of the transformation.

5.3. Running the Simulation of the Anti-Apoptotic PI3K/AKT Pathway

After entering all required information and setting the initial parameters, the system is now ready to run the PI3K/AKT pathway simulation. Biologically, apoptosis is initiated once normal cells turn into abnormal cells, carrying out a self-destruction mechanism. However, the

cancer cell survives by producing survival factors that initiate anti-apoptotic pathway. PI3K/AKT signaling pathway is initiated when a survival factor (SF), binds to its receptor (RTK). This event triggers the first reaction of PI3K/AKT signaling pathway, leading the signal to the final activation of transcription factors in the nucleus and, consequently, the activation of transcription of proteins that allow the cell to survive and proliferate—see **Figure 5**. The existence of the reactant SF in the membrane BTS is the main triggering event for our simulation. Once the reactant SF is available in the membrane BTS, the biochemical engine chooses the only eligible reaction for execution—*i.e.*, Equation (1).

$$RTK + SF \rightarrow RTK^* @ cytosol.$$
 (1)

Once active RTK—*i.e.*, RTK^{*}—and after a short, non-deterministic period of time (defined by Gillespie algorithm and ruled by probability), the chemical engine chooses and performs one of two eligible chemical reactions of the cytosol BTS—*i.e.*, Equations (2) and (3).

$$RTK^* + PI3K \rightarrow PI3K^* + RTK.$$
 (2)

$$RTK^* + Ras \rightarrow Ras^* + RTK^*.$$
(3)

Which one among the two reactions is picked for execution by the biochemical engine—given both the identical initial rates and the interaction 1:1 between reactants —depends on the free concentration for each reagent involved in the reaction.

The production of $PI3K^*$ and, consequently, the incremental availability of this one in the cytosol BTS lead PIP3 activation and thus the amplification of the original signal, as shown in Equation (4) to Equation (10).

$$PI3K^* + PIP3 \rightarrow PIP3^* + PI3K^*.$$
(4)

$$PI3K^* + AKT \rightarrow AKT^* + PI3K^*.$$
 (5)

$$PIP3^* + AKT \to AKT^*.$$
 (6)

$$PIP3^* + PDK1 \rightarrow PDK1^*.$$
 (7)

$$PIP3^* + PDK2 \rightarrow PDK2^*.$$
 (8)

 $PDK1^* + AKT \rightarrow AKT^* + PDK1.$ (9)

$$PDK2^* + AKT \rightarrow AKT^* + PDK2.$$
 (10)

Figure 7 shows the phase of the simulation where the activation of AKT (AKT^{*}) have taken place. AKT activation allows the sequential activation of a series of reagents and hence cell survival and proliferation. AKT target proteins can be classified into three distinct groups:

anti-apoptotic proteins, anti-p53 and proteins promoting cell proliferation. In the PI3K/AKT simulation the phosphorylation of these target proteins is represented in Equation (11) to Equation (17).

$$AKT^* + IKK \to IKK^* + AKT.$$
(11)

 $AKT^* + XIAP \rightarrow XIAP^*$ @ nucleus + AKT^* . (12)

$$AKT^* + Raf1 \rightarrow Raf1^* @ nucleus + AKT^*.$$
 (13)

$$AKT^* + GSK3^* \to GSK3 + AKT.$$
(14)

$$AKT^* + Mdm2 \rightarrow Mdm2^* + AKT.$$
(15)

$$AKT^* + TSC1 \rightarrow TSC1^* + AKT.$$
(16)

$$AKT^* + TSC2 \rightarrow TSC2^* + AKT.$$
(17)

Figures 8 and **9** show the variation in levels of reactants and products during signal transduction to achieve the activation of many downstream effector proteins e.g., IKK, XIAP, Raf1 and Mdm2. Thus, the signal transduction goes ahead until reaching the activation of transcription factors in the *nucleus* BTS.

As mentioned above, in each execution cycle the action selection mechanism—through the Gillespie algorithm—determines: 1) how long to wait before becomes active again, and 2) which reaction execute among all eligible chemical reactions.



Figure 7. Execution of the reactions involved in the first segment of the simulation: from SF binding to AKT activation. At the bottom of the graph can be seen all the reactants implicated in these reactions. The symbol "*" refers to active/phos- pho-rylated state of the reactant.



Figure 8. Execution of the reactions involved in the second segment of the simulation: from activation of AKT to activation of many downstream effector proteins. At the bottom of the graph can be seen all the reactants implicated in these reactions. The symbol "*" refers to active/phosphorylated state of the reactant.

🛃 Reactants Concen	tration by Time					
All Compartments						-
Compartment cytosol	Reactant	Quantity				
cytosol	PIP3*	10	-			
cytosol	Bcl2	4				
cytosol	SHIP2	4				
cytosol	AKT*	4				
cytosol	Raf1	2				
cytosol	PDK1	26				
cytosol	Ras*	62				
cytosol	PDK2	24				
cytosol	BcIXL*	2				
cytosol	Mdm2	3				
cytosol	RTK*	1				
cytosol	p53	3				
cytosol	PDK2*	16				
cvtosol	GSK3	1				
cytosol	PI3K*	4				-
cytosol	IKK	4			1	
nucleus	GSK3*	0		Time :	79685	
nucleus	TSC1*	0		121101126		
nucleus	p21Cip1*	3				
nucleus	BcIXL	2				
nucleus	cyclinD1	1				
nucleus	Raf1*	1				
nucleus	mTOR	11				
nucleus	AKT	12				
nucleus	mTOR*	13				
nucleus	p70S6K*	7				
nucleus	p70S6K	0				
nucleus	p21Cip1	1				
nucleus	TSC1	40				
nucleus	XIAP*	1				
nucleus	GSK3	2				
nucleus	AKT*	0				
nucleus	TSC2	4				
nucleus	cyclinD1*	3	-			

Figure 9. Variations of reactant concentrations in time. Second segment of the simulation: from activation of AKT to activation of many downstream effector proteins.

Upon simulating this anti-apoptotic pathway, we observed that a cancer cell escapes death, but if components PTEN and SHIP2 are present in the signaling system—in Equations (18) and (19)—then de cell stops growing and dies—see **Figure 10**.

$$PTEN^* + PIP3^* \rightarrow PIP3 + PTEN.$$
(18)

$$SHIP2^* + PI3K^* \rightarrow PI3K + SHIP2.$$
(19)

However, if simultaneously with the activation of PI3K, Ras is active, then this latter also activates PI3K, although PTEN and SHIP2 are present, according to Equation (20).

$$\operatorname{Ras}^* + \operatorname{PI3K} \to \operatorname{PI3K}^* + \operatorname{Ras}.$$
 (20)

🍰 Time Chart

Figure 11 shows how the mere presence of active Ras allows the cell to survive even in the presence of regulators of the PI3K/AKT pathway.

As shown in **Figures 7** to **11**, the proposed tool successfully simulated the effect of dietary polyphenols on

4 Reactants Concentration by Time

All Compartments

the inhibition of the anti-apoptotic PI3K/AKT pathway, which is a great first step in predicting the molecular mechanism explaining how dietary polyphenols can inhibits cancer cell growth.

6. Conclusions

Time Chart

¥

Phenolic compounds are ubiquitous in plant foods, and therefore, significant quantities are consumed in our daily diet, and play an important role in both the prevention and the pathogenesis of many chronic diseases.

One of our existing research areas focuses on molecular mechanism for polyphenols activity, and we are using *in vivo*, *in vitro* and in silico models. First, we perform in silico modeling for caspase pathway. In this work, we model the anti-apoptotic PI3K/AKT pathway in the absence or presence of phenolic compounds, using BTS-SOC-based model. This platform will be helpful in planning future experiments *in vitro* when we integrate it with different antiapoptotic pathways.

Compartment Reactant Quantity GSK3* mitochondria membrane SE RTK membrane 9 cytosol GSK3 PIP3 272 cvtosol BAD1433* cytosol 3 cvtosol XIAP BAD1433 cytosol 1 cytosol Mdm2* cytosol AKT cytosol PI3K 0.000 300.000 400.000 450,000 500.000 350.000 PDK1 cvtosol Time PTFN* cytosol 11 cytosol Ras 162 SC2 -> n70S6K -+ PI3K -+ n21Cin1* -+ PDK1 p53* cytosol 2 + Raf1 🔸 BcIXL* - BcI2 - PIP3 - IKK XIAP cytosol PIP3 1 I3K* 🕂 Ras 🔫 RTK* \Rightarrow cyclinD1 🔸 GSK3 🕁 p21Cip1 Bcl2 4 cytoso 284355 Time : cytosol AKT m2* 🔹 PDK2* 💷 p53 🛥 BcIXL 🛨 XIAP* 🔶 Raf1* cytosol Raf1 ers cytosol PDK1 40 cytosol Ras* 594 cytosol PDK2 40 cytosol BCIXL Mdm2 2 cvtosol RTK* cytosol 1 cytosol n53 cytosol PDK2 SHIP2 cytosol 4 PI3K* cvtosol 0 nucleus GSK3* nucleus SC1 p21Cip1* nucleus nucleus BcIXL 3

Figure 10. The presence of PTEN and SHIP 2, as well as the activation of p53, cause the cell to stop growing and die.

		🐁 Time Chart			_	
					Time	Chart
					Time	Chart
Reactants Concer	ntration by Time					
	induction by the					
All Compartments					-	
Compartment	Reactant	Quantity				
mitochondria	GSK3*	0	-			
membrane	SF	0		1		
membrane	RTK	9				
cytosol	GSK3*	1				
cytosol	PIP3	278				
cytosol	BAD1433*	3				
cytosol	XIAP	4				100000 10000 100000 100000
cytosol	BAD1433	1				
cytosol	AKT	6				
cytosol	PI3K	4				Provent and address of the second
cytosol	PDK1*	0				100,000, 100,000, 140,000, 160,000, 100,000
cytosol	PTEN*	11				100,000 120,000 140,000 160,000 180,000
cytosol	Ras	637				lime
cytosol	p53*	3		=		
cytosol	PIP3*	0	-1			
cytosol	Bcl2	4			-	P 🖚 Rafi 🔸 BCIXL* 🛹 BCI2 🔹 Ras 🗣 PIP3 📥 IKK
cytosol	AKT*	0			<u> </u>	XL 🛶 RTK* 🐡 Ras* 🥌 p21Cip1 🛨 GSK3 🔷 cyclinD1
cytosol	IKK*	1		Time: 186077		(1* IKK*
cytosol	Raf1	3				
cytosol	PDK1	40				ers
cvtosol	Ras*	119				
cytosol	PDK2	40				
cytosol	BcIXL*	2				
cytosol	Mdm2	4				
cytosol	RTK*	1				
cvtosol	p53	1				
cvtosol	SHIP2*	4				
cytosol	GSK3	1				
cytosol	PI3K*	0				
Cytosol	IKK	3				
nucleus	GSK3*	0				
nucleus	TSC1*	0				
nucleus	p21Cip1*	3				
nucleus	BcIXL	2				
nucleus	cvclinD1	1				

Figure 11. Active Ras allows the cell to survive even in the presence of PTEN and SHIP2.

7. Acknowledgements

The authors would like to thank Andrea Boccacci for making a valuable contribution to this project.

REFERENCES

- [1] V. Cheynier, "Polyphenols in Foods Are More Complex Than Often Thought," *The American Journal of Clinical Nutrition*, Vol. 81, No. 1, 2005, pp. 223S-229S.
- [2] A. Scalbert, A. C.Manach, C. Morand, C. Remesy and L. Jimenez, "Dietary Polyphenols and the Prevention of Diseases," *Critical Reviews in Food Science and Nutrition*, Vol. 45, No. 4, 2005, pp. 287-306. doi:10.1080/1040869059096
- [3] I. Naasani, F. Oh-Hashi, T. Oh-Hara, W.Y. Feng, J. Johnston, K. Chan and T. Tsuruo, "Blocking Telomerase by Dietary Polyphenols Is a Major Mechanism for Limiting the Growth of Human Cancer Cells *in Vitro* and *in Vivo*," *Cancer Research*, Vol. 63, No. 4, 2003, pp. 824-830.
- [4] T. Hussain, S. Gupta, V. M. Adhami and H. Mukhtar, "Green Tea Constituent Epigallocatechin-3-Gallate Selec-

tively Inhibits COX-2 without Affecting COX-1 Expression in Human Prostate Carcinoma Cells," *International Journal of Cancer*, Vol. 113, No. 4, 2005, pp. 660-669. doi:10.1002/ijc.20629

- [5] K.A. O'Leary, S. De Pascual-Tereasa, P. W. Needs, Y. P. Bao, N. M. O'Brien and G. Williamson, "Effect of Flavonoids and Vitamin E on Cyclooxygenase-2 (COX-2) Transcription," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, Vol. 551, No. 1-2, 2004, pp. 245-254. doi:10.1016/j.mrfmmm.2004.01.015
- [6] C. D. Sadik, H. Sies and T. Schewe, "Inhibition of 15-Lipoxygenases by Flavonoids: Structure-Activity Relations and Mode of Action," *Biochemical Pharmacology*, Vol. 65, No. 5, 2003, pp. 773-781. doi:10.1016/S0006-2952(02)01621-0
- [7] T. Schewe, C. Sadik, L. O. Klotz, T. Yoshimoto, H. Kuhn and H. Sies, "Polyphenols of Cocoa: Inhibition of Mammalian 15-Lipoxygenase," *Biological Chemistry*, Vol. 382, No. 12, 2001, pp. 1687-1696. doi:10.1515/BC.2001.204
- [8] S. Wiseman, T. Mulder and A. Rietveld, "Tea Flavonoids: Bioavailability *in Vivo* and Effects on Cell Signalling

Pathways *in Vitro*," *Antioxidants & Redox Signaling*, Vol. 3, No. 6, 2001, pp. 1009-1021. doi:10.1089/152308601317203549

- [9] D. F. Birt, S. Hendrich and W. Wang, "Dietary Agents in Cancer Prevention: Flavonoids and Isoflavonoids," *Pharmacology & Therapeutics*, Vol. 90, No. 2-3, 2001, pp. 157-177.
- [10] P. M. Kris-Etherton and C. L. Keen, "Evidence That the Antioxidant Flavonoids in Tea and Cocoa Are Beneficial for Cardiovascular Health," *Current Opinion in Lipidol*ogy, Vol. 13, No. 1, 2002, pp. 1341-1349. doi:10.1097/00041433-200202000-00007
- [11] M. Artico, R. Di Santo, R. Costi, E. Novellino, G. Greco, S. Massa, *et al.*, "Geometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling," *Journal of Medicinal Chemistry*, Vol. 41, No. 21, 1998, pp. 3948-3960. doi:10.1021/jm9707232
- [12] H. K. Biesalski, "Polyphenols and Inflammation: Basic Interactions," *Current Opinion in Clinical Nutrition & Metabolic Care*, Vol. 10, No. 6, 2007, pp. 724-728. doi:10.1097/MCO.0b013e3282f0cef2
- [13] I. Rahman, S. K. Biswas and P. A. Kirkham, "Regulation of Inflammation and Redox Signalling by Dietary Polyphenols," *Biochemical Pharmacology*, Vol. 72, No. 11, 2006, pp. 1439-1452. <u>doi:10.1016/j.bcp.2006.07.004</u>
- [14] C. Manach, A. Mazur and A. Scalbert, "Polyphenols and Prevention of Cardiovascular Disease," *Current Opinion in Lipidology*, Vol. 16, No. 1, 2005, pp. 77-84. doi:10.1097/00041433-200502000-00013
- [15] C. L. Hsu and G. C. Yen, "Phenolic Compounds: Evidence for Inhibitory Effects against Obesity and Their Underlying Molecular Signalling Mechanisms," *Molecular Nutrition & Food Research*, Vol. 52, No. 1, 2008, pp. 53-61. doi:10.1002/mnfr.200700393
- [16] K. M. Nicholson and N. G. Anderson, "The Protein Kinase B/Akt Signalling Pathway in Human Malignancy," *Cellular Signalling*, Vol. 14, No. 5, 2002, pp. 381-395. doi:10.1016/S0898-6568(01)00271-6
- [17] M. Viroli and M. Casadei, "Biochemical Tuple Spaces for Self-Organising Coordination," In: J. Field and V. T. Vasconcelos, Eds., *Coordination Languages and Models*, *ser. LNCS*, Springer, Lisbon, 2009, pp. 143-162. doi:10.1007/978-3-642-02053-7_8
- [18] A. Omicini and E. Denti, "From Tuple Spaces to Tuple Centres," Science of Computer Programming, Vol. 41, No. 3, 2001, pp. 277-294. doi:10.1016/S0167-6423(01)00011-9
- [19] A. Omicini and F. Zambonelli, "Coordination for Internet Application Development," *Autonomous Agents and Multi-Agent Systems*, Vol. 2, No. 3, 1999, pp. 251-269, doi:10.1023/A:1010060322135
- [20] D. Gelernter, "Generative Communication in Linda," ACM Transactions on Programming Languages and Systems, Vol. 7, No. 1, 1985, pp. 80-112. <u>http://portal.acm.org/citation.cfm?id=2433</u>
- [21] P. P. González-Pérez, A. Omicini and M. Sbaraglia, "A Biochemically-Inspired Coordination-Based Model for

- [22] D. T. Gillespie, "Exact Stochastic Simulation of Coupled Chemical Reactions," *The Journal of Physical Chemistry*, Vol. 81, No. 25, 1977, pp. 2340-2361. doi:10.1021/j100540a008
- [23] O. Tokgun, H. Akca, R. Mammadov, C. Aykurt and G. Deniz, "Convolvulus galaticus, Crocus antalyensis, and Lilium candidum Extracts Show Their Antitumor Activity Through Induction of p53-Mediated Apoptosis on Human Breast Cancer Cell Line MCF-7," Journal of Medicinal Food, Vol. 15, No. 11, 2012, pp. 1000-1005. doi:10.1089/jmf.2012.0050
- [24] L. S. Po, T. T. Wang, Z. Y. Chen and L. K. Leung, "Genistein-Induced Apoptosis in MCF-7 Cells Involves Chan- ges in Bak and Bcl-x without Evidence of Anti-Oestro- genic Effects," *British Journal of Nutrition*, Vol. 88, No. 5, 2002 pp. 463-469. doi:10.1079/BJN2002693
- [25] Y. J. Surh, "Cancer Chemoprevention with Dietary Phytochemicals," *Nature Reviews Cancer*, Vol. 3, No. 10, 2003 pp. 768-780. <u>doi:10.1038/nrc1189</u>
- [26] D. L. Smith, L. K. Nolden, G. B. Mills and Y. Lu, "Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling," In: D. A. Gewirtz, S. E. Holt and S. Grant, Eds., *Apoptosis, Senescence and Cancer*, Humana Press, New Jersey, 2007, pp. 313-334. doi:10.1007/978-1-59745-221-2_17
- [27] W. Vanden Berghe, "Epigenetic Impact of Dietary Polyphenols in Cancer Chemoprevention: Lifelong Remodeling of Our Epigenomes," *Pharmacological Research*, Vol. 65, No. 6, 2012, pp. 565-576. doi:10.1016/j.phrs.2012.03.007
- [28] G. Kroemer, L. Galluzzi and C. Brenner, "Mitochondrial Membrane Permeabilization in Cell Death," *Physiological Reviews*, Vol. 87, No. 1, 2007, pp. 99-163. doi:10.1152/physrev.00013.2006
- [29] J. Hoshino, E. J. Park, T. P. Kondratyuk, L. Marler, J. M. Pezzuto, R. B. van Breemen, S. Mo, Y. Li and M. Cushman, "Selective Synthesis and Biological Evaluation of Sulfate-Conjugated Resveratrol Metabolites," *Journal of Medicinal Chemistry*, Vol. 53, No. 13, 2010, pp. 5033-5043. doi:10.1021/jm100274c
- [30] G. Lauritzen, C. M. Stock, J. Lemaire, S. F. Lund, M. F. Jensen, B. Damsgaard, K. S. Petersen, M. Wiwel, L. Rønnov-Jessen, A. Schwab and S. F. Pedersen, "The Na+/H+ Exchanger NHE1, But Not the Na⁺, HCO₃(-) Cotransporter NBCn1, Regulates Motility of MCF7 Breast Cancer Cells Expressing Constitutively Active ErbB2," *Cancer Letters*, Vol. 317, No. 2, 2012, pp. 172-183.
- [31] K. Yu, L. Toral-Barza, C. Shi, W. G. Zhang and A. Zask, "Response and Determinants of Cancer Cell Susceptibility to PI3K Inhibitors," *Cancer Biology & Therapy*, Vol. 7, No. 2, 2008, pp. 307-315. doi:10.4161/cbt.7.2.5334
- [32] G. Gao, C. Chen, Y. Yang, H. Yang, J. Wang, Y. Zheng, Q. Huang and X. Hu, "Targeted Detecting HER2 Expression with Recombinant Anti HER2 ScFv-GFP Fusion Antibody," *Sheng Wu Gong Cheng Xue Bao*, Vol. 28, No.

8, 2012, pp. 1002-1014.

- [33] T. Wang, M. Zhang, Z. Ma, K. Guo, V. Tergaonkar, Q. Zeng and W. Hong, "A Role of Rab7 in Stabilizing EGFR-Her2 and in Sustaining Akt Survival Signal," *Journal of Cellular Physiology*, Vol. 2227, No. 6, 2012, pp. 2788-2797. <u>doi:10.1002/jcp.23023</u>
- [34] C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, P. Dent and C. Mol, "Extrinsic Pathway- and Cathepsin-Dependent Induction of Mitochondrial Dysfunction Are Essential for Synergistic Flavopiridol and Vorinostat Lethality in Breast Cancer Cells," *Cancer Therapy Journal*, Vol. 12, No. 1, 2007, pp. 3101-3112. doi:10.1158/1535-7163.MCT-07-0561
- [35] X. He, Y. Wang, J. Zhu, M. Orloff and C. Eng, "Resveratrol Enhances the Anti-Tumor Activity of the mTOR Inhibitor Rapamycin in Multiple Breast Cancer Cell Lines Mainly by Suppressing Rapamycin-Induced AKT Signaling," *Cancer Letters*, Vol. 301, No. 2, 2011, pp. 168-176. doi:10.1016/j.canlet.2010.11.012
- [36] A. D. Balgi, G. H. Diering, E. Donohue, K. K. Lam, B. D. Fonseca, C. Zimmerman, M. Numata and M. Roberge, "Regulation of mTORC1 Signaling by pH," *Plos One*, Vol. 6, No. 6, 2011, e21549.
- [37] C. Garofalo, D. Sisci and E. Surmacz, "Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells," *Clinical Cancer Research*,

Vol. 10, No. 19, 2004, pp. 6466-6475. doi:10.1158/1078-0432.CCR-04-0203

- [38] W. Wang, E. R. Rayburn, S. E. Velu, D. H. Nadkarni, S. Murugesan and R. Zhang, "In Vitro and in Vivo Anticancer Activity of Novel Synthetic Makaluvamine Ana- logues," Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3511-3518. doi:10.1158/1078-0432.CCR-08-2689
- [39] T. Sakamoto, H. Horiguchi, E. Oguma and F. Kayama, "Effects of Diverse Dietary Phytoestrogens on Cell Growth, Cell Cycle and Apoptosis in Estrogen-Receptor-Positive Breast Cancer Cells," *The Journal of Nutritional Biochemistry*, Vol. 21, No. 9, 2012, pp. 856-864. doi:10.1016/j.jnutbio.2009.06.010
- [40] L.Q Li, X. L. Li, L. Wang, W. J. Du, R. Guo, H. H. Liang, X. Liu, D. S. Liang, Y. J. Lu, H. L. Shan and H. C. Jiang, "Matrine Inhibits Breast Cancer Growth via miR-21/ PTEN/Akt Pathway in MCF-7 Cells," *Cellular Physiol*ogy and Biochemistry, Vol. 30, No. 3, 2012, pp. 631-641. doi:10.1159/000341444
- [41] M. S. Sheikh, M. Garcia, Q. Zhan, Y. Liu and A. J. Fornace Jr., "Cell Cycle-Independent Regulation of p21-Waf1/Cip1 and Retinoblastoma Protein during Okadaic Acid-Induced Apoptosis Is Coupled with Induction of Bax Protein in Human Breast Carcinoma Cells," *Cell Growth & Differentiation*, Vol. 7, No. 12, 1996, pp. 1599-1607.